$ 750.78
Key Takeaways
Risk factor
Very vulnerable to price shocks
Profitability factor
Greatly overvalued vs peers
About
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive
Target Price
The average target price of ARGX is 857 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
